An update from KalVista Pharmaceuticals (KALV) is now available.
Benjamin L. Palleiko has been appointed as the new CEO of KalVista Pharmaceuticals, Inc., while also joining the Board of Directors. He retains his roles as President and CFO with an amended employment agreement that includes a base salary of $661,800, a 60% bonus target, and specific severance benefits in certain termination scenarios. Additionally, he received 250,000 restricted stock units. Meanwhile, the outgoing CEO, T. Andrew Crockett, has resigned without disputes and will receive a severance package including 18 months’ salary and other benefits. The company has issued a press release regarding these executive changes.
See more data about KALV stock on TipRanks’ Stock Analysis page.
